Search Results

Your search for David M. O’Malley, MD, and Antonio Castaneda, MD,David M. O’Malley, MD, and Antonio Castaneda, MD matches 2 pages

Showing 1 - 2

By David M. O’Malley, MD, and Antonio Castaneda, MD / September 10, 2020 - Supplement: Gynecologic Cancers Almanac

Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both poly (ADP-ribose) polymerase (PARP) inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG...

gynecologic cancers

By David M. O’Malley, MD, and Antonio Castaneda, MD / May 10, 2020

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...

Nov

Today In Oncology

Search Results

Your search for David M. O’Malley, MD, and Antonio Castaneda, MD,David M. O’Malley, MD, and Antonio Castaneda, MD matches 2 pages

Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis Monitoring and Treatment